Company: VCYT
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001384101-25-000110
Chunk: 35

Company: VERACYTE, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
 Other cost of biopharmaceutical and other revenue (3)1,462 1,271 2,506 2,221 Allocation of facilities and IT expenses458 469 872 896 Total cost of biopharmaceutical and other revenue3,572 3,812 6,270 6,650 Intangible asset amortization - cost of revenue2,667 2,909 5,252 5,824 Gross profit89,769 77,913 169,277 140,381 Operating expenses:Research and development:Compensation expense9,063 8,365 18,812 17,450 Direct research and development expense3,292 5,243 7,434 9,117 Other research and development expenses (4)1,880 1,339 3,692 2,857 Allocation of facilities and IT expenses2,029 1,518 4,046 3,006 Total research and development16,264 16,465 33,984 32,430 Selling and marketing:Compensation expense17,601 17,081 35,236 34,703 Direct marketing expense1,478 2,048 2,188 3,186 Other selling and marketing expenses (5)3,696 3,212 7,549 6,627 Allocation of facilities and IT expenses2,541 1,875 4,797 3,482 Total selling and marketing25,316 24,216 49,770 47,998 General and administrative:Compensation expense21,260 23,107 41,433 40,866 Other general and administrative expenses (6)19,734 15,444 41,624 30,481 Allocation of facilities and IT expenses(8,663)(6,806)(16,918)(13,392)Total general and administrative32,331 31,745 66,139 57,955 Impairment of assets20,505 — 20,505 429 Intangible asset amortization - operating expenses621 881 1,243 1,619 Other income, net(6,518)(2,755)(11,042)(5,503)Income tax provision2,230 1,627 2,611 1,583 Net income (loss)$(980)$5